Madrilenian Group of Cutaneous Lymphomas

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 marketed ·

Quick facts

Marketed products

PUVA (8-MOP + UVA) · Oncology
PUVA therapy uses 8-methoxypsoralen (8-MOP) as a photosensitizing agent combined with UVA radiation to induce apoptosis in malignant T cells and suppress immune-mediated skin inflammation.
PUVA (8MOP + UVA) + IFN · Oncology
PUVA (psoralen + UVA phototherapy) combined with interferon-alpha works by inducing apoptosis of malignant T cells through photochemical DNA damage and enhancing immune-mediated tumor cell destruction.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Madrilenian Group of Cutaneous Lymphomas

What are Madrilenian Group of Cutaneous Lymphomas's marketed drugs?

Top marketed products include PUVA (8-MOP + UVA), PUVA (8MOP + UVA) + IFN.

PUVA (8-MOP + UVA) · Oncology
PUVA (8MOP + UVA) + IFN · Oncology
Sector hub: All tracked pharma companies